San Francisco, CA, United States of America

Alexander B H Bakker

This inventor holds 7 USPTO granted patents. Top assignees: Schering Corporation, Crucell Holland B.v.. Active years: 2002-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alexander B H Bakker. Retrieved from https://idiyas.com/inventor/alexander-b-h-bakker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 28.6

Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 92(Granted Patents)

Location History:

San Francisco, CA (US) (2002 - 2008)
Hillegom, NL (2009)
Leiden, NL (2010 - 2011)

Company Filing History:

Years Active: 2002-2011

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7959922 - Liquid anti-rabies antibody formulations (2011-06-14),

2. 7659093 - DAP12 nucleic acids (2010-02-09),

3. 7579446 - Binding molecules capable of neutralizing rabies virus and uses thereof (2009-08-25),

4. 7332574 - MDL-1 polypeptides (2008-02-19),

5. 7319140 - Binding compounds to DAP12 proteins (2008-01-15),

6. 6953843 - Antibodies and fragments thereof to MDL-1 protein (2005-10-11),

7. 6416973 - Nucleic acids encoding mammalian cell membrane protein MDL-1 (2002-07-09),

Title: Alexander B H Bakker: Innovator in Pharmaceutical Antibody Formulations

Introduction

Alexander B H Bakker is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of antibody therapies. With a total of 7 patents, Bakker's work has had a meaningful impact on medical science.

Latest Patents

Bakker's latest patents include innovative formulations that address critical health issues. One of his notable inventions is the "Liquid anti-rabies antibody formulations," which provides pharmaceutical antibody formulations for the post-exposure prophylaxis of rabies. This invention is crucial for preventing the disease after potential exposure. Another significant patent is related to "DAP12 nucleic acids," which involves the purification and isolation of genes encoding mammalian cell surface polypeptides. This patent offers nucleic acids, proteins, antibodies, and other reagents that are useful in modulating the development of lymphoid and myeloid cells.

Career Highlights

Throughout his career, Bakker has worked with prominent companies in the pharmaceutical industry. He has been associated with Schering Corporation and Crucell Holland B.V., where he contributed to various research and development projects. His expertise in antibody formulations has positioned him as a valuable asset in these organizations.

Collaborations

Bakker has collaborated with esteemed colleagues in his field, including Joseph H Phillips and Lewis L Lanier. These collaborations have further enhanced his research and development efforts, leading to innovative solutions in pharmaceutical science.

Conclusion

Alexander B H Bakker is a distinguished inventor whose work in pharmaceutical antibody formulations has made a significant impact on medical science. His contributions, particularly in the area of rabies prevention and cell development modulation, highlight his innovative spirit and dedication to improving health outcomes.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]